Abstract
National Cancer Institute, Bethesda, MD, and Memorial Sloan Kettering Cancer Center, New York, NY Corresponding author: Sham Mailankody, MBBS, Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065; e-mail: mailanks@mskcc. org. Randomized clinical trials in cancer medicine are increasingly conducted in lowand middle-income countries (LMICs). The proper way to conduct such studies is complex and the subject of much debate. Two key questions outline the debate. First, what is the appropriate control arm for such studies? For example, when can trials use placebo or some control less than global best practice? Second, what obligations do trial sponsors have toward host nations and communities?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
